Key Points
- Director Harold Shlevin sold 16,790 shares on Dec. 9 at an average price of $6.27 for proceeds of $105,273.30, reducing his direct stake by about 59.97% to 11,206 shares (~$70,261.62).
- Galectin Therapeutics (GALT) opened at $5.36, has a one‑year range of $0.73–$6.66, a market cap of $345.49M and a negative P/E (-9.29); the company missed quarterly EPS expectations, reporting ($0.13) vs. an expected ($0.11).
- Analyst and institutional backdrop is mixed: MarketBeat shows a consensus "Hold" with an average target of $6.00 (one Buy, one Sell), while institutions like Vanguard have modestly increased positions and institutional investors own about 11.68% of the stock.
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) Director Harold Shlevin sold 16,790 shares of the firm's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $6.27, for a total transaction of $105,273.30. Following the completion of the sale, the director directly owned 11,206 shares of the company's stock, valued at approximately $70,261.62. This represents a 59.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Galectin Therapeutics Price Performance
GALT stock opened at $5.36 on Thursday. Galectin Therapeutics Inc. has a 1 year low of $0.73 and a 1 year high of $6.66. The company has a market cap of $345.49 million, a P/E ratio of -9.29 and a beta of 0.95. The firm has a 50-day moving average of $5.37 and a 200 day moving average of $3.96.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities research analysts expect that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several brokerages have commented on GALT. HC Wainwright reissued a "buy" rating and set a $6.00 price objective on shares of Galectin Therapeutics in a research report on Thursday, August 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Galectin Therapeutics has a consensus rating of "Hold" and an average target price of $6.00.
Get Our Latest Analysis on Galectin Therapeutics
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Galectin Therapeutics by 2.9% in the third quarter. Vanguard Group Inc. now owns 2,247,967 shares of the company's stock worth $9,520,000 after acquiring an additional 63,419 shares in the last quarter. Osaic Holdings Inc. raised its position in shares of Galectin Therapeutics by 3.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,265,384 shares of the company's stock worth $2,670,000 after purchasing an additional 41,968 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Galectin Therapeutics in the 2nd quarter worth about $1,580,000. Wealthspire Advisors LLC boosted its stake in Galectin Therapeutics by 20.4% in the 2nd quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company's stock worth $1,012,000 after purchasing an additional 81,144 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its position in Galectin Therapeutics by 8.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company's stock valued at $516,000 after purchasing an additional 34,300 shares during the last quarter. Hedge funds and other institutional investors own 11.68% of the company's stock.
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
